EMPAGLOXIT contains Empagliflozin, a SGLT2 inhibitor that have been approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. SGLT2 inhibitors are also known to help improve outcomes in people with heart disease, kidney disease, and heart failure. For this reason, these medications are often used in people with type 2 diabetes who also have heart or kidney problems.
EMPAGLOXIT
COMPOSITION:
Empagliflozin 10 mg / 25 mg Tablets
MODE OF ACTION:
Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule.
INDICATIONS
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease. To reduce the risk of sustained decline in eGFR, end-stage kidney disease, adults with chronic kidney disease at risk of progression.
DOSAGE
Recommended dosage is 10 mg orally once daily in the morning, taken with or without food. For additional glycemic control, dosage may be increased to 25 mg orally once daily in patients tolerating Empagliflozin.
STORAGE
Store at room temperature not exceeding 30ᵒC.
DISCLAIMER
This information is for the medical professionals & registered medical practitioners only. This product must be consumed with the valid prescription of registered medical practitioners.*Images/Pack are for representation purpose only.